Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Amvitral Z is a multi-ingredient nutritional supplement and oral rehydration product developed by Amvia Biotech. It is formulated as an oral powder containing dextrose, sucrose, zinc, and copper sulphate, typically packaged in 105 gm or 210 gm containers. The product is designed to address electrolyte and trace element deficiencies, particularly those resulting from diarrhea-related fluid loss. Dextrose and sucrose facilitate the co-transport of sodium and water across the intestinal epithelium via the sodium/glucose cotransporter 1 (SGLT1), aiding in rapid rehydration. Zinc is included for its role in reducing the duration and severity of diarrheal episodes and supporting immune function, while copper sulphate provides additional essential mineral supplementation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Amvitral Z.